[go: up one dir, main page]

EE03157B1 - Omeprasooli enantiomeerid, nende valmistamise protsess ja neid sisaldavad ravimpreparaadid - Google Patents

Omeprasooli enantiomeerid, nende valmistamise protsess ja neid sisaldavad ravimpreparaadid

Info

Publication number
EE03157B1
EE03157B1 EE9400363A EE9400363A EE03157B1 EE 03157 B1 EE03157 B1 EE 03157B1 EE 9400363 A EE9400363 A EE 9400363A EE 9400363 A EE9400363 A EE 9400363A EE 03157 B1 EE03157 B1 EE 03157B1
Authority
EE
Estonia
Prior art keywords
omeprazole
preparation
enantiomers
pharmaceutical preparations
preparations containing
Prior art date
Application number
EE9400363A
Other languages
English (en)
Estonian (et)
Inventor
Lennart Lindberg Per
Oskar Sverker Von Unge Per
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE03157(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of EE03157B1 publication Critical patent/EE03157B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
EE9400363A 1993-05-28 1994-11-17 Omeprasooli enantiomeerid, nende valmistamise protsess ja neid sisaldavad ravimpreparaadid EE03157B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939301830A SE9301830D0 (sv) 1993-05-28 1993-05-28 New compounds

Publications (1)

Publication Number Publication Date
EE03157B1 true EE03157B1 (et) 1999-02-15

Family

ID=20390088

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9400363A EE03157B1 (et) 1993-05-28 1994-11-17 Omeprasooli enantiomeerid, nende valmistamise protsess ja neid sisaldavad ravimpreparaadid

Country Status (42)

Country Link
US (5) US5693818A (xx)
EP (3) EP1020460B1 (xx)
JP (3) JP3549111B2 (xx)
KR (1) KR100337274B1 (xx)
CN (2) CN1055469C (xx)
AT (1) ATE197452T1 (xx)
CA (2) CA2337581A1 (xx)
CL (1) CL2009000805A1 (xx)
CY (1) CY2224B1 (xx)
CZ (1) CZ287876B6 (xx)
DE (4) DE69426254T2 (xx)
DK (3) DK0652872T3 (xx)
DZ (1) DZ1785A1 (xx)
EE (1) EE03157B1 (xx)
ES (3) ES2326404T3 (xx)
FI (2) FI117755B (xx)
GR (2) GR970300012T1 (xx)
HR (1) HRP940307B1 (xx)
HU (1) HU226824B1 (xx)
IL (1) IL109684A (xx)
IS (1) IS1854B (xx)
LT (1) LT3287B (xx)
LU (1) LU91870I2 (xx)
LV (1) LV11034B (xx)
MA (1) MA23210A1 (xx)
MY (1) MY121192A (xx)
NO (2) NO307378B1 (xx)
NZ (1) NZ266915A (xx)
PL (1) PL178994B1 (xx)
PT (3) PT1020460E (xx)
RU (1) RU2137766C1 (xx)
SA (2) SA05260103B1 (xx)
SE (1) SE9301830D0 (xx)
SG (1) SG49283A1 (xx)
SI (2) SI9420002B (xx)
SK (1) SK282524B6 (xx)
TN (1) TNSN94058A1 (xx)
TW (1) TW389761B (xx)
UA (1) UA60289C2 (xx)
WO (1) WO1994027988A1 (xx)
YU (1) YU49065B (xx)
ZA (1) ZA943557B (xx)

Families Citing this family (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
CZ289804B6 (cs) * 1994-07-08 2002-04-17 Astrazeneca Ab Multijednotková tabletovaná dávková forma I
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
HRP960232A2 (en) * 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
PT1037607E (pt) * 1997-12-08 2004-07-30 Altana Pharma Ag Nova forma de supositorio compreendendo um composto activo instavel em acido
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
KR100627614B1 (ko) * 1998-04-20 2006-09-25 에자이 가부시키가이샤 안정화된 벤즈이미다졸계 화합물 함유 조성물로 이루어지는 의약제제
NZ510180A (en) 1998-08-10 2002-11-26 Univ California Prodrugs of the pyridyl-methylsulphonyl-benzimidazole type proton pump inhibitors
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
UA72748C2 (en) * 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
BR9915421A (pt) 1998-11-18 2001-08-07 Astrazeneca Ab Processo para a fabricação de sais alcalinos levemente solúveis ou menos solúveis de heterociclos de sulfinila substituìda, forma de dosagem farmacêutica, uso da mesma, método de tratamento de doenças gastrointestinais, e, processo para a fabricação de uma forma de dosagem farmacêutica.
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
AU5871000A (en) * 1999-06-11 2001-01-02 Paul G. Abrams High dose radionuclide complexes for bone marrow suppression
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
CA2382867A1 (en) * 1999-08-26 2001-03-01 Applied Analytical Industries, Inc. Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
EP1595879A3 (en) * 1999-08-26 2010-01-27 aaiPharma Inc. Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262085B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
WO2001024780A2 (en) * 1999-10-01 2001-04-12 Natco Pharma Limited Soft gel capsule resistant to gastric juices
DK1222922T3 (da) * 1999-10-20 2007-12-03 Eisai R&D Man Co Ltd Fremgangsmåde til stabilisering af benzimidazolforbindelser
SE9903831D0 (sv) 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
BR0017140A (pt) 2000-02-24 2004-05-25 Kopran Res Lab Ltd Derivados de benzimidazol anti-úlcera estáveis ácidos para administração oral
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
WO2001087831A2 (en) * 2000-05-15 2001-11-22 Ranbaxy Laboratories Limited Novel amorphous form of omeprazole salts
US6306435B1 (en) * 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
EP1306375B1 (en) 2000-08-04 2006-10-11 Takeda Pharmaceutical Company Limited Salts of benzimidazole compound and application thereof
CA2386716C (en) * 2002-05-17 2012-07-24 Bernard Charles Sherman Magnesium salt of s-omeprazole
AU2003204233B8 (en) * 2000-08-04 2008-06-26 Bernard Charles Sherman Magnesium salt of S-omeprazole
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
EP1390081A2 (en) 2001-01-08 2004-02-25 Neorx Corporation Therapeutic and diagnostic compounds, compositions, and methods
WO2002083608A2 (en) * 2001-04-13 2002-10-24 Apsinterm Llc Methods of preparing sulfinamide and sulfoxides
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
GB2376231A (en) * 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
WO2004009583A2 (en) * 2002-07-19 2004-01-29 Garst Michael E Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
CA2445513A1 (en) 2001-09-18 2003-03-27 Zeria Pharmaceutical Co., Ltd. Benzimidazole derivatives
MXPA04007169A (es) * 2002-01-25 2004-10-29 Santarus Inc Suministro transmucosal de inhibidores de bomba de protones.
DK1487818T3 (da) * 2002-03-05 2007-08-20 Astrazeneca Ab Alkylammoniumsalte af omeprazol og esomeprazol
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
US6894066B2 (en) * 2002-05-09 2005-05-17 Bernard Charles Sherman Magnesium salt of S-omeprazole
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
WO2004012659A2 (en) * 2002-08-01 2004-02-12 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
CA2501424A1 (en) 2002-08-30 2004-03-11 Dr. Reddy's Laboratories Limited Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
EP1552833B1 (en) 2002-10-16 2016-12-28 Takeda Pharmaceutical Company Limited Process for producing an amorphous optically active isomer of lansoprazole
BR0315574A (pt) * 2002-10-22 2005-09-20 Ranbaxy Lab Ltd Forma amorfa de esomeprazol, composição farmacêutica contendo o mesmo e processo para sua preparação
WO2004046134A2 (en) * 2002-11-18 2004-06-03 Dr. Reddy's Laboratories Limited Crystalline form ii of esomeprazole magnesium trihydrate and process for its preparation
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
AR042277A1 (es) 2002-12-06 2005-06-15 Altana Pharma Ag Un procedimiento para la preparacion de sulfinil benzimidazoles opticamente puros
KR101169471B1 (ko) 2002-12-06 2012-07-30 니코메드 게엠베하 (ｓ)-판토프라졸의 제조 방법
FR2848555B1 (fr) 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
WO2004066924A2 (en) * 2003-01-24 2004-08-12 Andrx Labs Llc Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
EP1603537A4 (en) * 2003-02-20 2009-11-04 Santarus Inc NOVEL FORMULATION, ANTICIPATED COMPLEX IMMEDIATE RELEASE FOR A FAST AND CONTINUOUS SUPPRESSION OF MAGIC ACID
MXPA05009183A (es) * 2003-02-28 2005-10-20 Ranbaxy Lab Ltd Polimorfos de s-omeprazol.
WO2004089935A1 (en) * 2003-04-10 2004-10-21 Hetero Drugs Limitd Novel crystalline forms of s-omeprazole magnesium
EP1633736A1 (en) * 2003-05-05 2006-03-15 Ranbaxy Laboratories Limited Barium salt of benzimidazole derivative
WO2004099182A1 (en) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Zinc salt of (s)-omeprazole
MXPA06000410A (es) * 2003-07-15 2006-03-17 Allergan Inc Procedimiento para preparar profarmacos isomericamente puros de inhibidores de la bomba de protones.
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1648416A4 (en) * 2003-07-18 2012-03-28 Santarus Inc PHARMACEUTICAL FORMULATIONS FOR INHIBITING THE ACIDIC ACIDIFICATION AND MANUFACTURING AND USE METHOD
CA2531566C (en) * 2003-07-18 2013-05-07 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
JP2006528158A (ja) * 2003-07-23 2006-12-14 アルタナ　ファルマ　アクチエンゲゼルシャフト プロトンポンプ阻害剤のアルカリ塩
CN100457104C (zh) * 2003-07-23 2009-02-04 尼科梅德有限责任公司 质子泵抑制剂的碱性盐
US20060165793A1 (en) * 2003-08-04 2006-07-27 Koji Ukai Pharmaceutical preparation to be dispersed before administration
SE0302382D0 (sv) * 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
WO2005027880A1 (en) * 2003-09-25 2005-03-31 Natco Pharma Limited Enteric soft gelatin capsule containing esomeprazole and method of preparation
EP1708684A2 (en) 2003-09-26 2006-10-11 Alza Corporation Drug coating providing high drug loading and methods for providing the same
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
AU2003272086A1 (en) * 2003-10-14 2005-04-27 Natco Pharma Limited Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation
GB0403165D0 (en) * 2004-02-12 2004-03-17 Ct Novel uses for proton pump inhibitors
BRPI0507784A (pt) * 2004-02-18 2007-07-17 Allergan Inc métodos e composições para a administração de pró-fármacos de inibidores da bomba de prótons
WO2005082338A2 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Prodrugs for the intravenous administration of proton pump inhibitors
SE0400410D0 (sv) 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
PT1740571E (pt) 2004-04-28 2009-09-02 Hetero Drugs Ltd Processo para preparar compostos de piridinilmetil-1hbenzimidazol na forma enantiomericamente enriquecida ou como enantiómeros únicos
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US7365206B2 (en) * 2004-05-28 2008-04-29 Hetero Drugs Limited Stereoselective synthesis of benzimidazole sulfoxides
US20050267159A1 (en) * 2004-05-28 2005-12-01 Aaipharma, Inc. Magnesium complexes of S-omeprazole
US20050267157A1 (en) * 2004-05-28 2005-12-01 David White Magnesium-S-omeprazole
WO2006001755A1 (en) * 2004-06-24 2006-01-05 Astrazeneca Ab A new esomeprazole sodium salt crystal modification
CN1972928A (zh) 2004-06-24 2007-05-30 阿斯利康(瑞典)有限公司 制备用于制备依美拉唑钠盐的结晶修饰物的新方法
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
KR100847635B1 (ko) * 2004-08-06 2008-07-21 에자이 알앤드디 매니지먼트 가부시키가이샤 벤즈이미다졸 유도체와 아민과의 염
CA2575718C (en) 2004-08-06 2010-12-14 Eisai R & D Management Co., Ltd. Salts of benzimidazole derivative with amines and process for manufacturing the same
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
WO2006066932A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
WO2006073779A1 (en) * 2004-12-30 2006-07-13 Transform Phamaceuticals, Inc. Novel omeprazole forms and related methods
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
ATE528301T1 (de) 2005-03-25 2011-10-15 Livzon Pharmaceutical Group Verfahren zur herstellung von substituierten sulfoxidzusammensetzungen
US20090298884A1 (en) * 2005-05-06 2009-12-03 Glenmark Generics Ltd. Esomeprazole Strontium Salt, Process For Its Preparation and Pharmaceutical Compositions Containing Same
WO2006121995A2 (en) * 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
EP1891043A1 (en) * 2005-06-15 2008-02-27 Hetero Drugs Limited Amorphous esomeprazole hydrate
KR100641534B1 (ko) * 2005-07-28 2006-11-01 한미약품 주식회사 에스오메프라졸 및 그의 염의 제조방법
WO2007019153A2 (en) * 2005-08-03 2007-02-15 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
US20070043085A1 (en) * 2005-08-19 2007-02-22 Glenmark Pharmaceuticals Limited Process for the preparation of amorphous form of neutral esomeprazole
WO2007031845A2 (en) * 2005-09-14 2007-03-22 Glenmark Pharmaceuticals Limited Polymorphic forms of (s)-omeprazole magnesium salts and processes for their preparation
JP2009511481A (ja) * 2005-10-06 2009-03-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド 増強された治療特性を持つ、胃Ｈ＋，Ｋ＋−ＡＴＰａｓｅの重水素化阻害剤
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
BRPI0619158A2 (pt) 2005-12-05 2011-09-20 Astrazeneca Ab processo para preparar forma que não que não seja sal de esomeprazol, composto, formulação farmacêutica, e, método de tratamento
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
ATE428707T1 (de) 2005-12-28 2009-05-15 Union Quimico Farma Verfahren zur herstellung des (s)-enantiomers von omeprazol
US8063074B2 (en) 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
AR056062A1 (es) * 2006-06-05 2007-09-19 Bago Sa Labor Composicion farmaceutica antiacida en forma de polvo, preparacion farmaceutica que la comprende y proceso para su preparacion
WO2007142580A1 (en) * 2006-06-07 2007-12-13 Astrazeneca Ab Novel method for preparation of ammonium salts of esomeprazole
US7863330B2 (en) * 2006-06-14 2011-01-04 Rottapharm S.P.A. Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders
BRPI0621832A2 (pt) 2006-07-05 2013-03-19 Lupin Ltd processo para a preparaÇço de enantiâmeros oticamente puros ou oticamente enriquecidos de compostos de sulfàxido
PL2046334T3 (pl) 2006-07-25 2015-02-27 Vecta Ltd Kompozycje i sposoby hamowania wydzielania kwasów żołądkowych z wykorzystaniem pochodnych małych kwasów dikarboksylowych w połączeniu z PPI
US20100317689A1 (en) * 2006-09-19 2010-12-16 Garst Michael E Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
WO2008067037A2 (en) 2006-10-05 2008-06-05 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
MX2009004475A (es) 2006-10-27 2009-08-12 Univ Missouri Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
AU2007323919A1 (en) * 2006-11-13 2008-05-29 Takeda Pharmaceuticals U.S.A., Inc. Methods for preserving renal function using xanthine oxidoreductase inhibitors
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
EP1947099A1 (en) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
MX2009007680A (es) * 2007-01-19 2011-08-03 Takeda Pharmaceuticals North America Inc Metodos para prevenir o reducir el numero de expansiones graduales de gota utilizando inhibidores de oxidoreductasa de xantina y agentes anti-inflamatorios.
EP2114919A2 (en) * 2007-01-31 2009-11-11 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic seperation
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
EP2186807B1 (en) 2007-02-21 2015-01-07 Cipla Limited Process for the preparation of esomeprazole magnesium dihydrate
KR101303813B1 (ko) * 2007-04-16 2013-09-04 에스케이케미칼주식회사 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법
RU2341524C1 (ru) * 2007-05-02 2008-12-20 Новосибирский институт органической химии им. Н.Н. Ворожцова СО РАН (НИОХ СО РАН) СПОСОБ ПОЛУЧЕНИЯ ОПТИЧЕСКИ АКТИВНОГО 5-МЕТОКСИ-2-((4-МЕТОКСИ-3,5-ДИМЕТИЛПИРИДИН-2-ИЛ)МЕТИЛСУЛЬФИНИЛ)-1Н-БЕНЗО[d]ИМИДАЗОЛА
EP2000468A1 (en) * 2007-05-09 2008-12-10 Dr. Reddy's Laboratories Ltd. Esomeprazole salts and processes for preparation thereof
ATE534643T1 (de) * 2007-06-07 2011-12-15 Aurobindo Pharma Ltd Verbessertes verfahren zur herstellung eines optisch aktiven protonenpumpenhemmers
CN101323609B (zh) * 2007-06-15 2013-05-01 成都福瑞生物工程有限公司 不对称氧化硫醚成亚砜合成对映体含量高的苯并咪唑衍生物的方法
PT2106397E (pt) 2007-09-25 2012-01-23 Hetero Drugs Ltd Processo para a preparação de esomeprazol enantiomericamente puro
US8106210B2 (en) 2007-10-08 2012-01-31 Hetero Drugs Limited Polymorphs of esomeprazole salts
FR2925899B1 (fr) * 2007-12-27 2012-12-21 Sidem Pharma Sa Procede de preparation enantioselective de sulfoxydes.
CA2716367C (en) 2008-02-20 2015-05-26 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
US20090280175A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Proton Pump Inhibitor Tablets
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
WO2009145368A1 (en) * 2008-05-27 2009-12-03 Sk Chemicals Co., Ltd. Improved preparing method of (s)-omeprazole from omeprazole racemate using optical resolution agent
EP2143722A1 (en) * 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
EP2147918A1 (en) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
CN102209529A (zh) 2008-09-09 2011-10-05 阿斯利康(瑞典)有限公司 将药物组合物递送至有需要的患者的方法
EP2264024A1 (en) 2008-10-14 2010-12-22 LEK Pharmaceuticals d.d. Process for the preparation of enantiomerically enriched proton pump inhibitors
WO2010058409A2 (en) 2008-11-18 2010-05-27 Hetero Research Foundation Optical purification of esomeprazole
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
CN102481293A (zh) 2009-06-25 2012-05-30 阿斯利康(瑞典)有限公司 治疗具有发展nsaid-相关的溃疡的风险的患者的方法
AU2010266026B2 (en) * 2009-06-25 2014-08-07 Nuvo Pharmaceuticals (Ireland) Designated Activity Company Method for treating a patient in need of aspirin therapy
EP2319504A1 (en) 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical solid dosage form
WO2011058569A1 (en) 2009-11-12 2011-05-19 Hetero Research Foundation Process for the resolution of omeprazole
WO2011080501A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2345408A3 (en) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Acid labile drug formulations
EP2534144B1 (en) 2010-02-12 2014-09-03 Esteve Química, S.A. Preparation process of the sodium salt of Esomeprazole
US20110207779A1 (en) * 2010-02-25 2011-08-25 Glenmark Generics Ltd Process for the preparation of esomeprazole magnesium
KR101797936B1 (ko) 2010-09-10 2017-11-15 다케다 파마슈티칼스 유에스에이, 인코포레이티드 테오필린과 페북소스타트의 병용 치료 방법
CN102816149B (zh) * 2011-06-10 2015-05-13 上海汇伦生命科技有限公司 一种高对映选择性合成(s)-奥美拉唑及其盐的制备方法
CN102807561A (zh) * 2011-06-21 2012-12-05 寿光富康制药有限公司 S-奥美拉唑铝盐及其制备方法和应用
CN102850323A (zh) * 2011-06-30 2013-01-02 秦引林 一种埃索美拉唑钠的精制方法
CN102321071B (zh) * 2011-07-20 2013-01-23 江苏奥赛康药业股份有限公司 一种高纯度埃索美拉唑钠的工业化生产方法
CN104844577A (zh) * 2011-07-31 2015-08-19 连云港润众制药有限公司 埃索美拉唑镁的晶型
WO2013081566A1 (en) 2011-11-25 2013-06-06 Mahmut Bilgic A formulation comprising benzimidazole
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
WO2013088109A1 (en) 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
WO2013101897A2 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN104203938A (zh) 2012-01-21 2014-12-10 朱比兰特生命科学有限公司 用于制备2-吡啶基甲基亚硫酰基苯并咪唑、它们的类似物和光学活性对映体的方法
CN103420978A (zh) * 2012-05-15 2013-12-04 上海医药工业研究院 一种苯并咪唑类化合物的镁盐的制备方法
CN102657622A (zh) * 2012-05-17 2012-09-12 康普药业股份有限公司 一种含有埃索美拉唑钠的冻干粉针剂的制备工艺
CN102964335B (zh) * 2012-11-13 2014-06-25 凌元敏 一种埃索美拉唑钠化合物及其制备方法和用途
CN103159737B (zh) * 2013-04-12 2014-03-19 四川省惠达药业有限公司 一种埃索美拉唑钠化合物及药物组合物
WO2015065848A1 (en) 2013-11-04 2015-05-07 Capsugel Belgium Nv Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole
EP2929885A1 (en) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
US10130618B2 (en) 2014-04-11 2018-11-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of dabigatran and proton pump inhibitors
CN104045627A (zh) * 2014-05-21 2014-09-17 丽珠医药集团股份有限公司 一种奥美拉唑纯化方法
CN104530003A (zh) * 2014-06-10 2015-04-22 广东东阳光药业有限公司 吡啶甲基亚磺酰基-1h-苯并咪唑类化合物的盐的制备方法
EP2980086B1 (en) 2014-07-29 2016-06-15 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Efficient process for the preparation of esomeprazole (S)-binol complex
CN107428726B (zh) 2014-12-26 2021-03-16 国立大学法人东京大学 光学活性的质子泵抑制剂化合物的制备方法
EP3064495B1 (en) 2015-03-06 2016-12-14 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Improved process for the preparation of optically pure esomeprazole
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN105924430A (zh) * 2016-06-27 2016-09-07 杭州富阳伟文环保科技有限公司 一种埃索美拉唑钠的精制方法
US10939686B2 (en) * 2017-04-11 2021-03-09 Mclaughlin Gormley King Company Sabadilla oil and uses thereof
CN108409714A (zh) * 2018-03-29 2018-08-17 成都通德药业有限公司 埃索美拉唑、埃索美拉唑盐及埃索美拉唑镁的制备方法
JP7645861B2 (ja) * 2019-07-16 2025-03-14 アメリカン リージェント， インコーポレイテッド ウマ科動物用エソメプラゾール製剤及び使用方法
EP4015044B1 (en) 2019-08-29 2024-05-29 Tokyo University of Science Foundation Method for preparing enantiomer of sulfoxide compound, and system for preparing enantiomer
RU2726320C1 (ru) * 2020-02-09 2020-07-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КемГМУ) Способ определения примесных компонентов омепразола
JP2025532389A (ja) 2022-10-04 2025-09-29 ザビリュク，アルセニー 大動脈弁の石灰化の抑制

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4636085A (en) * 1982-03-16 1987-01-13 Mapro Inc. Apparatus for removing volatiles from plastic materials delivered to an extrusion or injection molding machine
SE8204879D0 (sv) * 1982-08-26 1982-08-26 Haessle Ab Novel chemical intermediates
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
US4445708A (en) * 1983-05-09 1984-05-01 General Motors Corporation Energy absorbing steering column for vehicles
SE8403179D0 (sv) * 1984-06-13 1984-06-13 Haessle Ab New compounds
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5075323A (en) * 1988-08-24 1991-12-24 Aktiebolaget Hassle Compounds including omeprazole in the treatment of glaucoma
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
WO1994024867A1 (en) * 1993-04-27 1994-11-10 Sepracor, Inc. Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
CZ289804B6 (cs) * 1994-07-08 2002-04-17 Astrazeneca Ab Multijednotková tabletovaná dávková forma I
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
SE9704183D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New process
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound

Also Published As

Publication number Publication date
SK10195A3 (en) 1995-09-13
EP1020461B2 (en) 2015-10-21
SI9420002A (en) 1995-08-31
NZ266915A (en) 1996-10-28
NO2011009I1 (no) 2011-06-20
RU95105587A (ru) 1996-10-27
ATE197452T1 (de) 2000-11-11
NO950263D0 (no) 1995-01-24
MY121192A (en) 2006-01-28
SA94140756B1 (ar) 2006-05-20
PL178994B1 (pl) 2000-07-31
PT1020461E (pt) 2009-07-29
ES2326405T5 (es) 2016-02-15
JP4039999B2 (ja) 2008-01-30
LV11034A (lv) 1996-02-20
IS1854B (is) 2003-02-21
SE9301830D0 (sv) 1993-05-28
FI20070002L (fi) 2007-01-02
ES2326404T3 (es) 2009-10-09
SI22752A (sl) 2009-10-31
ES2099047T3 (es) 2001-03-01
TW389761B (en) 2000-05-11
EP1020461A2 (en) 2000-07-19
AU6902494A (en) 1994-12-20
CN1107503C (zh) 2003-05-07
DE69435220D1 (de) 2009-09-03
EP1020460B1 (en) 2009-07-22
SK282524B6 (sk) 2002-10-08
UA60289C2 (uk) 2003-10-15
YU31494A (sh) 1997-05-28
DZ1785A1 (fr) 2002-02-17
DK1020461T4 (en) 2016-02-15
KR100337274B1 (ko) 2003-12-31
CZ287876B6 (cs) 2001-03-14
LT3287B (en) 1995-06-26
ZA943557B (en) 1995-04-11
CL2009000805A1 (es) 2009-08-21
JP3959056B2 (ja) 2007-08-15
EP1020461A3 (en) 2006-10-04
HRP940307B1 (en) 2001-06-30
FI117755B (fi) 2007-02-15
EP0652872A1 (en) 1995-05-17
US5714504A (en) 1998-02-03
US20080312449A1 (en) 2008-12-18
HUT71888A (en) 1996-02-28
HK1008330A1 (en) 1999-05-07
EP1020460A3 (en) 2003-10-15
JP3549111B2 (ja) 2004-08-04
DK1020460T3 (da) 2009-08-10
CA2337581A1 (en) 1994-12-08
HU9500247D0 (en) 1995-03-28
JP2004043494A (ja) 2004-02-12
FI950377A0 (fi) 1995-01-27
KR950702553A (ko) 1995-07-29
AU676337B2 (en) 1997-03-06
EP1020461B1 (en) 2009-07-22
DE652872T1 (de) 1997-09-04
CN1259346A (zh) 2000-07-12
DK0652872T3 (da) 2001-03-05
CY2224B1 (en) 2003-04-18
HK1028045A1 (en) 2001-02-02
DE69435221D1 (de) 2009-09-03
HK1028044A1 (en) 2001-02-02
HU226824B1 (en) 2009-11-30
ES2099047T1 (es) 1997-05-16
DE69426254D1 (de) 2000-12-14
SI22752B (sl) 2010-01-29
JPH07509499A (ja) 1995-10-19
SI9420002B (sl) 2009-12-31
US5693818A (en) 1997-12-02
ES2326405T3 (es) 2009-10-09
IL109684A0 (en) 1994-12-29
DK1020461T3 (da) 2009-08-10
MA23210A1 (fr) 1994-12-31
EP1020460A2 (en) 2000-07-19
FI950377L (fi) 1995-01-27
IS4161A (is) 1994-11-29
LU91870I2 (fr) 2011-11-21
IL109684A (en) 2002-05-23
LV11034B (en) 1996-10-20
TNSN94058A1 (fr) 1995-04-25
EP0652872B1 (en) 2000-11-08
CA2139653C (en) 2001-07-10
JP2004043493A (ja) 2004-02-12
PL307261A1 (en) 1995-05-15
US6143771A (en) 2000-11-07
GR970300012T1 (en) 1997-05-31
CZ20295A3 (en) 1995-10-18
PT1020460E (pt) 2009-07-29
SA05260103B1 (ar) 2010-01-31
US20100222591A1 (en) 2010-09-02
LTIP1941A (en) 1994-12-27
WO1994027988A1 (en) 1994-12-08
YU49065B (sh) 2003-08-29
GR3035365T3 (en) 2001-05-31
CN1055469C (zh) 2000-08-16
PT652872E (pt) 2001-04-30
NO307378B1 (no) 2000-03-27
DE69426254T2 (de) 2001-06-07
SG49283A1 (en) 1998-05-18
NO950263L (no) 1995-01-24
HRP940307A2 (en) 1996-12-31
RU2137766C1 (ru) 1999-09-20
FI20070002A7 (fi) 2007-01-02
CA2139653A1 (en) 1994-12-08
CN1110477A (zh) 1995-10-18

Similar Documents

Publication Publication Date Title
EE03157B1 (et) Omeprasooli enantiomeerid, nende valmistamise protsess ja neid sisaldavad ravimpreparaadid
DK0648503T3 (da) Pro-prodrugs, deres fremstilling og anvendelse
GR920100570A (el) Παραγωγα 3(2η)-πυριδαζινονης και μεθοδος για την παρασκευη τους.
NO301767B1 (no) Salt av clavulansyre
HU886266D0 (en) Process for the production of medical preparations containing buspiron and its salts for peroral use
DK557189A (da) 1,2,3,4-tetrahydro-1,9-acridindiaminer, deres fremstilling og anvendelse som laegemidler
HUT45967A (en) Process for production of antipasmodic derivatives of n-/substituated phenil/-benzoil-amid
BR9101973A (pt) Compostos quimicos,processo para a sua preparacao e composicoes farmaceutica e terapeutica
MY102850A (en) New pharmaceutical preparation for oral use.
AU1753188A (en) Treating agents for renal diseases
NO171454C (no) Analogifremgangsmaate for fremstilling av den terapeutisk aktive forbindelse 6-(4-(-benzotiazolyl)-1-piperazinyl)-5,8-kinoksalindion

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

AA1Y Spc filed

Free format text: PRODUCT NAME: VIMOVO; REG NO/DATE: 714110 23.11.2010

Spc suppl protection certif: C20110006

Filing date: 20110516

MF4A Right revoked following opposition or revocation